查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933898

RNAi疗法市场按递送技术、治疗分子类型、研发阶段、给药途径、製剂类型、适应症和最终用户划分－全球预测，2026-2032年

RNAi Therapeutics Market by Delivery Technology, Therapeutic Molecule Type, Development Stage, Route Of Administration, Formulation Type, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 RNAi 疗法市场在 2025 年的价值为 55.4 亿美元，在 2026 年成长至 63.6 亿美元，到 2032 年达到 152.3 亿美元，复合年增长率为 15.53%。

主要市场统计数据
基准年 2025 55.4亿美元
预计年份：2026年 63.6亿美元
预测年份：2032年 152.3亿美元
复合年增长率 (%) 15.53%

RNA干扰疗法已从实验室研究发展成为核酸医学的核心支柱，这得益于精准基因静默机制和临床疗效的显着提升。其核心在于利用小干扰RNA（siRNA）及其相关构建体，透过细胞内讯号路径沉默致病标靶基因，为过去难以治癒的疾病提供了一种新的治疗途径。化学、偶联策略和递送平台的进步，系统性地降低了脱靶效应，提高了耐受性，并使药物在更广泛的适应症范围内展现出可预测的药理作用。

因此，临床计画目前探索的疾病领域已不再局限于遗传性代谢疾病，还包括复杂的肿瘤应用、传染性病原体和心血管标靶。生产技术、分析表征和监管政策的同步改进，降低了曾经限制转化研究进展的技术不确定性。更重要的是，以病人为中心的考量，例如皮下给药和延长疗效持续时间，正在重塑研发重点和商业性化模式。

总体而言，RNAi疗法的引入标誌着一种新的治疗方法走向成熟，成为一个可行的治疗领域。本执行摘要的其余部分概述了相关人员在分配资源、建立伙伴关係和规划临床专案时应考虑的最重要的科学、营运和策略发展。

变革性转变正在重新定义RNAi疗法：从递送创新到监管进展，再到跨学科合作，共同推动临床成功

近年来，RNAi疗法领域发生了一系列变革性变化，这些变化建立在递送技术、化学和监管实践的持续创新之上，从而重塑了该领域的格局。其中最显着的是标靶化偶联物和改良奈米颗粒系统的出现，它们能够实现器官选择性递送，同时限制全身暴露。例如，将药物标靶化肝细胞的GalNAc样受体以及用于肝外分布的特化脂质奈米颗粒製剂，都很好地体现了递送技术的进步如何开闢了新的靶点类别和给药模式。

评估2025年美国关税措施对RNAi供应链、製造成本、临床开发时间表和国际合作动态的累积影响

2025年美国关税措施为RNAi的研发和生产带来了新的营运复杂性，影响了组件成本、供应商选择和跨境合作。对某些进口原料、特殊脂质和特定电子元件征收的关税导致采购成本增加，促使专案发起公司重新评估其供应商布局。由于先进的递送系统通常依赖国际采购的专有脂质、偶联物和客製化API的组合，成本结构的转变正迫使各公司实现采购多元化，并协商长期供应协议以确保专案按时完成。

从适应症、给药平台、分子类型、研发阶段、给药途径、製剂和最终用户需求模式等方面进行关键细分洞察

详细的細項分析揭示了科学机会与商业性需求在适应症、递送技术、分子类型、研发阶段、给药途径、製剂方法和最终用户画像等因素交汇之处。适应症细分涵盖心血管疾病、感染疾病、代谢性疾病、肿瘤和罕见疾病。在肿瘤领域，研发人员的目标既包括骨髓恶性肿瘤，也固态肿瘤。其中，骨髓恶性肿瘤的研究进一步细分为白血病、淋巴瘤和骨髓瘤，而固态肿瘤的研究则着重于乳癌、肝癌和肺癌。如此广泛的治疗领域要求采用标靶递送策略和生物标记主导的测试设计，以将各种疗法的优势与尚未满足的需求相匹配。

影响RNAi技术应用的区域趋势：对美洲、欧洲、中东和非洲以及亚太地区的研发、生产和市场进入的影响

全球RNAi生态系中存在区域差异，这些差异既带来了机会，也带来了限制，美洲、欧洲、中东和非洲以及亚太地区呈现出截然不同的发展趋势。在美洲，生物技术创新、创业投资和临床试验基础设施的集中，有利于快速转化应用和早期商业化。然而，高昂的研发成本和复杂的支付方环境，使得制定完善的市场进入计画变得至关重要。在该地区，生技公司与大型製药公司之间的合作十分常见，旨在加速后期研发和分销策略。

企业策略、竞争定位和伙伴关係趋势推动RNAi疗法领域的创新和商业化路径

在RNAi领域营运的公司正采取差异化的策略，以体现其技术优势、规模扩张目标和伙伴关係策略。一些公司专注于平台卓越性，大力投资于递送技术，旨在将药物作用范围扩展到肝臟以外，并提高肿瘤和中枢神经系统标靶的治疗指数。另一些公司则强调临床深度，将资源集中在有限的高价值适应症，并推动具有明确转化途径的后期研发专案。平台所有者与以治疗为导向的申办者之间的跨领域合作仍然很普遍，这种合作将递送技术与特异性疾病的临床专业知识相结合。

为产业领导者提供切实可行的建议，以加速临床转换、确保供应链的韧性、优化交付平台并降低商业化风险。

产业领导者应优先采取以下切实可行的措施，将科学潜力转化为可持续的临床和商业性价值。首先，投资于多样化的给药方式，以降低单一平台风险。优先选择在可生产性、组织特异性和监管清晰度方面取得平衡的技术。其次，透过建立多源采购、确保区域生产选项以及为关键脂质偶联物检测试剂建立策略性库存缓衝，来增强供应链韧性。第三，在研发规划早期阶段就整合健康经济学和真实世界证据框架，以支持报销谈判，并向支付方和医疗保健系统展示长期价值。

调查方法详细介绍了用于综合 RNAi 市场情报的多源证据收集、同行检验、分析框架和品管。

本研究综合分析基于严谨的多面向方法，结合了专家面对面访谈和全面的证据综合。关键见解源自于对研发高管、生产和供应链高管、临床研究人员以及监管顾问的结构化访谈，旨在获取关于技术成熟度和营运挑战的实地观点。此外，还系统性地回顾了同行评审文献、会议报告、监管指导文件和公司资讯披露，以确保技术说明和战略趋势反映公开可获得的证据。

总结RNAi疗法中的技术进步、营运挑战、策略重点和相关人员机会

RNAi疗法领域正处于转折点，平台成熟度、递送技术创新以及策略营运选择将决定哪些项目能够取得临床和商业性成功。标靶化偶联物、奈米颗粒工程和寡核苷酸化学的进步显着拓展了RNAi疗法的适应症范围，而监管政策的明确化和生产过程的改进也消除了一些传统的临床应用障碍。同时，供应链风险、关税带来的成本压力以及对强有力的卫生经济学证据的需求等营运挑战，也要求申办方制定深思熟虑的策略应对措施。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 RNAi疗法市场：依递送技术划分

  • 外泌体
  • GalNAc缀合物
  • 脂质奈米颗粒
  • 聚合物奈米粒子
  • 病毒载体

9. 依治疗分子类型分類的RNAi疗法市场

  • 微型RNA
  • 短髮夹RNA
  • 小干扰RNA

第十章 RNAi疗法市场依研发阶段划分

  • 商业的
  • 第一阶段测试
  • 第二阶段
  • 第三阶段
  • 临床前阶段

第十一章 RNAi疗法市场依给药途径划分

  • 鼻腔给药
  • 静脉注射
  • 玻璃体内注射
  • 皮下注射

第十二章：按製剂类型分類的RNAi疗法市场

  • 液体配方
  • 冷冻干燥製剂

第十三章 RNAi疗法市场（依适应症划分）

  • 心血管疾病
  • 感染疾病
  • 代谢性疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
      • 白血病
      • 淋巴瘤
      • 多发性骨髓瘤
    • 固态肿瘤
      • 乳癌
      • 肝癌
      • 肺癌
  • 罕见疾病

第十四章 RNAi疗法市场（以最终用户划分）

  • 学术机构
  • 医院
  • 研究所
  • 专科诊所

第十五章 RNAi疗法市场：按地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：RNAi疗法市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国RNAi疗法市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国RNAi疗法市场

第十七章：中国的RNAi疗法市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • Benitec Biopharma Limited
  • Dynacure SAS
  • Novartis AG
  • OliX Pharmaceuticals, Inc.
  • Ona Therapeutics SL
  • Phio Pharmaceuticals Corp.
  • Quark Pharmaceuticals, Inc.
  • Roche Holding AG
  • Silence Therapeutics plc
  • Simaomics, Inc.
Product Code: MRR-C36616F699B1

The RNAi Therapeutics Market was valued at USD 5.54 billion in 2025 and is projected to grow to USD 6.36 billion in 2026, with a CAGR of 15.53%, reaching USD 15.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.54 billion
Estimated Year [2026] USD 6.36 billion
Forecast Year [2032] USD 15.23 billion
CAGR (%) 15.53%

RNA interference therapeutics have transitioned from laboratory curiosity to a core pillar of nucleic acid medicine, driven by precise gene-silencing mechanisms and growing clinical validation. At their core, small interfering RNAs and related constructs harness endogenous cellular pathways to downregulate disease-driving targets, offering therapeutic approaches for conditions historically deemed intractable. Advances in chemistry, conjugation strategies, and delivery platforms have systematically reduced off-target activity and improved tolerability, enabling predictable pharmacology for a broader range of indications.

As a consequence, clinical programs now explore diverse disease spaces beyond inherited metabolic disorders, including complex oncology applications, infectious agents, and cardiovascular targets. Parallel improvements in manufacturing, analytical characterization, and regulatory clarity have reduced technical uncertainties that once constrained translational momentum. Importantly, patient-centric considerations such as subcutaneous administration and extended durability of effect are reshaping development priorities and commercial access models.

Taken together, the introduction of RNAi therapeutics represents a maturation of a novel modality into an actionable therapeutic class. The remainder of this executive summary synthesizes the most consequential scientific, operational, and strategic developments that stakeholders must weigh when allocating resources, forming partnerships, and planning clinical programs.

Transformative shifts redefining RNAi therapeutics from delivery breakthroughs to regulatory progress and cross-disciplinary convergence enabling clinical success

Recent years have produced a set of transformative shifts that now define the RNAi therapeutic landscape, rooted in persistent innovation across delivery, chemistry, and regulatory practice. The most visible change is the emergence of targeted conjugates and refined nanoparticle systems that enable organ-selective delivery with lower systemic exposure. GalNAc-style receptor targeting for hepatocytes and tailored lipid nanoparticle formulations for extrahepatic distribution exemplify how delivery advances have unlocked new target classes and dosing paradigms.

Complementing delivery progress, improvements in oligonucleotide design and stabilization chemistries have enhanced potency and durability, permitting less frequent dosing and more convenient routes of administration. This has significant implications for patient adherence and health system uptake. Moreover, the field is experiencing a cross-disciplinary convergence: insights from gene-editing, biologics manufacturing, and immuno-oncology are being integrated into RNAi program design, accelerating combination strategies and novel therapeutic concepts.

Regulatory agencies have matured in their approach to nucleic acid therapeutics, providing clearer expectations for nonclinical safety packages, bioanalytics, and comparability studies. As a result, sponsors are able to de-risk program development earlier, enabling more ambitious clinical hypotheses. Collectively, these shifts are reducing translational friction, broadening therapeutic applicability, and reframing commercial and clinical strategies across the ecosystem.

Assessing the cumulative impact of United States tariffs 2025 on RNAi supply chains, manufacturing costs, clinical timelines, and global collaboration dynamics

United States tariff policies implemented in 2025 have introduced a new layer of operational complexity for RNAi development and manufacturing, influencing component costs, supplier selection, and cross-border collaboration. Tariffs on certain imported raw materials, specialized lipids, and select electronic equipment have translated into increased procurement costs and prompted sponsors to reassess supplier footprints. Because advanced delivery systems often rely on a mix of proprietary lipids, conjugates, and custom APIs sourced internationally, shifting cost structures have encouraged firms to diversify sourcing and negotiate longer-term supply agreements to preserve program timelines.

In parallel, clinical operations have been affected through altered logistics economics for cold-chain shipments and lab consumables. Sponsors undertaking global trials have experienced the need to reallocate budget and adjust site selection criteria where import-related costs are material. These constraints have not only prompted operational adaptations but have accelerated conversations about regional manufacturing capacity and on-shoring of critical components to reduce exposure to tariff volatility and transit disruptions.

Strategically, the tariff environment has increased the value of vertical integration and partnership models that secure upstream inputs. It has also encouraged procurement teams to pursue design-for-supply strategies that reduce dependence on tariff-vulnerable inputs, such as selecting alternative excipients or platform components with more geographically diversified supply chains. In sum, the cumulative impact of tariff shifts is reshaping procurement, manufacturing planning, and clinical logistics in ways that favor resilient, diversified operational models.

Key segmentation insights across indications, delivery platforms, molecule types, development stages, administration routes, formulations, and end-user demand patterns

A nuanced segmentation lens reveals where scientific opportunity and commercial demand intersect across indications, delivery technologies, molecule types, development stages, routes of administration, formulation approaches, and end-user profiles. Indication segmentation spans cardiovascular disorders, infectious diseases, metabolic disorders, oncology, and rare diseases; within oncology, developers pursue both hematological malignancies and solid tumors, with hematological workstreams further subdivided into leukemia, lymphoma, and myeloma while solid tumor efforts concentrate on breast, liver, and lung cancer. This therapeutic breadth calls for targeted delivery strategies and biomarker-driven trial designs that match modality strengths to unmet clinical needs.

Delivery technology segmentation covers exosomes, GalNAc conjugates, lipid nanoparticles, polymeric nanoparticles, and viral vectors, each offering different tissue tropisms, manufacturing challenges, and regulatory pathways. Therapeutic molecule types include microRNA constructs, short hairpin RNA, and small interfering RNA, which diverge in mechanism nuance and intracellular processing requirements. Development stage segmentation ranges from commercial to Phase I, Phase II, Phase III, and preclinical programs, reflecting a pipeline spectrum that demands tailored regulatory and manufacturing strategies at each milestone.

Route-of-administration segmentation encompasses intranasal, intravenous, intravitreal, and subcutaneous approaches, with implications for patient experience, clinical setting, and device integration. Formulation type segmentation distinguishes between liquid and lyophilized presentations, affecting stability profiles and logistics. Finally, end-user segmentation includes academic institutions, hospitals, research laboratories, and specialty clinics, highlighting the diverse stakeholder base that shapes adoption dynamics and clinical trial site readiness. Together, these segmentation axes guide prioritization of R&D investments and operational design, underscoring the need for adaptable platforms and targeted commercialization models.

Regional dynamics shaping RNAi adoption across the Americas, Europe Middle East & Africa, and Asia-Pacific with implications for R&D, manufacturing, and market access

Regional variation drives both opportunity and constraint across the global RNAi ecosystem, with distinct dynamics observable in the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, concentration of biotech innovation, venture capital, and clinical trial infrastructure supports rapid translational activity and early commercialization, though high development costs and complex payor landscapes require sophisticated market access planning. Collaboration between biotechs and large pharmaceutical partners often accelerates late-stage development and distribution strategies within this region.

Across Europe Middle East & Africa, regulatory harmonization and well-established public healthcare systems shape evidence expectations and reimbursement pathways, prompting sponsors to prioritize robust health economics data and real-world evidence strategies. Regional manufacturing capabilities and strong scientific hubs offer opportunities for localized production and clinical partnerships, particularly when market access proofs are required for public payors. In the Asia-Pacific region, a combination of large patient populations, expanding clinical research capacity, and growing manufacturing capabilities creates a compelling environment for scaling late-stage programs and cost-effective production. Regulatory authorities in this region have increasingly adopted pragmatic frameworks for nucleic acid therapeutics, which can shorten timelines for local development and registration when aligned with global dossiers.

Taken together, these regional distinctions inform where to site clinical programs, how to structure supply chains, and which evidence strategies will most effectively support adoption and reimbursement across diverse healthcare systems.

Company strategies, competitive positioning, and partnership trends driving innovation and commercialization pathways in the RNAi therapeutics landscape

Companies operating in the RNAi space are pursuing differentiated strategies that reflect their technological core, scale ambitions, and partnership approaches. Some organizations focus on platform excellence, investing heavily in delivery technologies designed to expand tissue reach beyond the liver and to improve therapeutic indices for oncology and central nervous system targets. Others emphasize clinical depth by concentrating resources on a narrow set of high-value indications and advancing late-stage assets with clear translational pathways. Cross-sector collaborations between platform owners and therapeutic-focused sponsors remain prevalent, combining delivery know-how with disease-specific clinical expertise.

Strategic M&A and licensing activity continues to be a lever for rapid capability acquisition, enabling firms to integrate proprietary chemistries or manufacturing know-how without building in-house capabilities from scratch. Manufacturing partnerships and capacity agreements are also a core element of corporate strategy, as firms seek to secure reliable supply and predictable timelines. From an organizational perspective, successful companies typically align clinical, CMC, and regulatory functions early to ensure comparability and analytics scale with program advancement. Finally, companies that invest in payer engagement and health economics evidence generation earlier in development tend to face fewer barriers at launch, particularly for treatments addressing chronic conditions or large patient populations.

Actionable recommendations for industry leaders to accelerate clinical translation, secure resilient supply chains, optimize delivery platforms, and de-risk commercialization

Industry leaders should prioritize a set of actionable moves to translate scientific promise into sustainable clinical and commercial value. First, invest in delivery diversification to mitigate single-platform risk; prioritize technologies that offer a balance of manufacturability, tissue specificity, and regulatory clarity. Second, strengthen supply chain resilience by establishing multi-source procurement, regional manufacturing options, and strategic inventory buffers for critical lipids, conjugates, and analytical reagents. Third, integrate health economics and real-world evidence frameworks into development plans early to support reimbursement discussions and to demonstrate long-term value to payors and health systems.

Fourth, foster strategic partnerships that pair delivery platform owners with disease-focused clinical teams, thereby accelerating molecule advancement while sharing development risk. Fifth, design clinical programs with patient-centric administration routes and dosing intervals that improve adherence and broaden potential settings of care. Sixth, prioritize regulatory engagement through early scientific advice and iterative dialogue on nonclinical package composition and comparability strategies. Finally, build cross-functional decision forums that align R&D, manufacturing, regulatory, and commercial stakeholders to accelerate go/no-go decisions and ensure readiness for scale-up once clinical validation milestones are achieved.

Research methodology detailing multi-source evidence gathering, expert validation, analytical frameworks, and quality controls used to synthesize RNAi market intelligence

This research synthesis is grounded in a rigorous, multi-method approach that combined primary expert engagement with comprehensive evidence synthesis. Primary insights were derived from structured interviews with senior R&D leaders, manufacturing and supply chain executives, clinical investigators, and regulatory advisors to capture frontline perspectives on technological maturation and operational challenges. These conversations were supplemented by systematic review of peer-reviewed literature, conference proceedings, regulatory guidance documents, and company disclosures to ensure that technical descriptions and strategic trends reflect publicly available evidence.

Analytical frameworks included cross-sectional segmentation mapping, scenario-based impact analysis for supply chain and tariff dynamics, and qualitative triangulation to reconcile differing expert viewpoints. Quality control processes entailed reproducibility checks, source triangulation for key assertions, and validation of technical terminology with subject-matter experts. Where necessary, discrepancies were resolved through follow-up consultations to ensure clarity and factual alignment. The methodology emphasizes transparency in evidence sources and interpretive steps, enabling readers to understand how strategic conclusions were reached and where ongoing data collection may be most valuable.

Conclusion synthesizing technological advances, operational challenges, strategic priorities, and opportunities for stakeholders in RNAi therapeutics

The RNAi therapeutics landscape is at an inflection point where platform maturity, delivery innovation, and strategic operational choices determine which programs will achieve clinical and commercial impact. Advances in targeted conjugates, nanoparticle engineering, and oligonucleotide chemistries have materially broadened feasible indications, while regulatory clarity and improved manufacturing practices have reduced several historical barriers to translation. At the same time, operational challenges such as supply chain exposure, tariff-induced cost pressures, and the need for robust health economics evidence require deliberate strategic responses from sponsors.

Ultimately, organizations that align technological capability with resilient operational design and payer-aware development strategies will be best positioned to convert scientific promise into patient benefit and sustainable business outcomes. The synthesis and recommendations presented here are intended to inform executive decision-making across R&D, manufacturing, and commercial functions, enabling stakeholders to prioritize investments, forge productive partnerships, and accelerate the responsible delivery of RNAi therapeutics to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNAi Therapeutics Market, by Delivery Technology

  • 8.1. Exosomes
  • 8.2. GalNAc Conjugates
  • 8.3. Lipid Nanoparticles
  • 8.4. Polymeric Nanoparticles
  • 8.5. Viral Vectors

9. RNAi Therapeutics Market, by Therapeutic Molecule Type

  • 9.1. Microrna
  • 9.2. Short Hairpin Rna
  • 9.3. Small Interfering Rna

10. RNAi Therapeutics Market, by Development Stage

  • 10.1. Commercial
  • 10.2. Phase I
  • 10.3. Phase Ii
  • 10.4. Phase Iii
  • 10.5. Preclinical

11. RNAi Therapeutics Market, by Route Of Administration

  • 11.1. Intranasal
  • 11.2. Intravenous
  • 11.3. Intravitreal
  • 11.4. Subcutaneous

12. RNAi Therapeutics Market, by Formulation Type

  • 12.1. Liquid Formulation
  • 12.2. Lyophilized Formulation

13. RNAi Therapeutics Market, by Indication

  • 13.1. Cardiovascular Disorders
  • 13.2. Infectious Diseases
  • 13.3. Metabolic Disorders
  • 13.4. Oncology
    • 13.4.1. Hematological Malignancies
      • 13.4.1.1. Leukemia
      • 13.4.1.2. Lymphoma
      • 13.4.1.3. Myeloma
    • 13.4.2. Solid Tumors
      • 13.4.2.1. Breast Cancer
      • 13.4.2.2. Liver Cancer
      • 13.4.2.3. Lung Cancer
  • 13.5. Rare Diseases

14. RNAi Therapeutics Market, by End User

  • 14.1. Academic Institutions
  • 14.2. Hospitals
  • 14.3. Research Laboratories
  • 14.4. Specialty Clinics

15. RNAi Therapeutics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. RNAi Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. RNAi Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States RNAi Therapeutics Market

19. China RNAi Therapeutics Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Alnylam Pharmaceuticals, Inc.
  • 20.6. Arbutus Biopharma Corporation
  • 20.7. Arbutus Biopharma Corporation
  • 20.8. Arrowhead Pharmaceuticals, Inc.
  • 20.9. Benitec Biopharma Limited
  • 20.10. Dynacure SAS
  • 20.11. Novartis AG
  • 20.12. OliX Pharmaceuticals, Inc.
  • 20.13. Ona Therapeutics SL
  • 20.14. Phio Pharmaceuticals Corp.
  • 20.15. Quark Pharmaceuticals, Inc.
  • 20.16. Roche Holding AG
  • 20.17. Silence Therapeutics plc
  • 20.18. Simaomics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GALNAC CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GALNAC CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GALNAC CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MICRORNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MICRORNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MICRORNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SHORT HAIRPIN RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SHORT HAIRPIN RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SHORT HAIRPIN RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GCC RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. GCC RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 230. GCC RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. G7 RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. G7 RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. G7 RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 263. G7 RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. NATO RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. NATO RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. NATO RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. NATO RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 274. NATO RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 275. NATO RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)